Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies

Nucleosides, Nucleotides and Nucleic Acids

Volumn 30, Issue 12, 2011, Pages 1324-1340

  Fernández Calotti, Paula X ^a   Colomer, Dolors ^b   Pastor Anglada, Marçal ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic lymphocytic leukemia; Nucleoside analogs; Nucleoside transporters

Indexed keywords

ABC TRANSPORTER; AZACITIDINE; CHLORAMBUCIL; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; FORODESINE; GEMCITABINE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INTERLEUKIN 4; MULTIDRUG RESISTANCE PROTEIN; NELARABINE; NITROBENZYLTHIOINOSINE; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRANSPORTER; PENTOSTATIN; PREDNISONE; RETINOIC ACID; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA1; VINCRISTINE;

ARTICLE; BIOAVAILABILITY; CELL MEMBRANE; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; DRUG TRANSPORT; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; MANTLE CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; HEMATOLOGIC NEOPLASMS; HUMANS; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES;

EID: 84855898514     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2011.597372     Document Type: Article

References (97)

1. Robak, T.; Lech-Maranda, E.; Korycka, A.; Robak, E. Purine nucleoside analogs as immunosuppressive ans antineoplastic agents: mechanism of action and clinical activity. Curr. Med. Chem. 2006, 13, 3165-3189. (Pubitemid 44680862)
2. Pettit, A. R. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br. J. Haematol. 2003, 121, 692-702.
3. Korycka, A.; Lech-Maranda, E.; Robak, T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat. Anticancer. Drug Discov. 2008, 3, 123-136.
4. Tsuzuki, M.; Handa, K.; Yamamoto, K.; Hasegawa, A.; Yamamoto, Y.; Watanabe, M.; Mizuta, S.; Maruyama, F.; Okamoto, M.; Emi, N.; Ezaki, K. Chronic myeloid leukemia following chemotherapy with 5'-deoxy-5-fluorouridine for gastric cancer. Intern. Med. 2008, 47(19), 1739-1741.
5. Wang, W. S.; Tzeng, C. H.; Chiou, T. J.; Liu, J. H.; Hsieh, R. K.; Yen, C. C.; Chen, P. M. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jpn J. Clin. Oncol. 1997, 27(3), 154-157.
6. Burnett, A.; Wetzler, M.; Lowenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 2011, 29(5), 487-494.
7. Jabbour, E.; Cortes, J. E.; Giles, F. J.; O'Brien, S.; Kantarjian, H. M. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007, 109(11), 2171-2181. (Pubitemid 46801546)
8. Shah, M.; Agarwal, B. Recent advances in management of acute myeloid leukemia (AML). Indian J. Pediatr. 2008, 75(8), 831-837.
9. Wong, A.; Soo, R. A.; Yong, W. P.; Innocenti, F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 2009, 41(2), 77-88.
10. Robak, T.; Korycka, A.; Lech-Maranda, E.; Robak, P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009, 14(3), 1183-1226.
11. Bellezza, I.; Tucci, A.; Minelli, A. 2-Chloroadenosine and human prostate cancer cells. Anticancer Agents Med. Chem. 2008, 8(7), [783-789.
12. Hentosh, P.; Peffley, D. M. The cladribine conundrum: deciphering the drug's mechanism of action. Expert Opin. Drug Metab. Toxicol. 2010, 6(1), 75-81.
13. Robak, T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat. Rev. 2006, 32(5), 365-376. (Pubitemid 44087867)
14. Sauter, C.; Lamanna, N.; Weiss, M. A. Pentostatin in chronic lymphocytic leukemia. Expert Opin. Drug Metab. Toxicol. 2008, 4(9), 1217-1222.
15. Parker, W. B.; Secrist, J. A. III; Waud, W. R. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr. Opin. Investig. Drugs 2004, 5(6), 592-596.
16. Faderl, S.; Gandhi, V.; Keating, M. J.; Jeha, S.; Plunkett, W.; Kantarjian, H. M. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 2005, 103(10), 1985-1995. (Pubitemid 40605104)
17. Pui, C. H.; Jeha, S.; Kirkpatrick, P. Clofarabine. Nat. Rev. Drug Discov. 2006, 4, 369-370. (Pubitemid 40704114)
18. Balakrishnan, K.; Nimmanapalli, R.; Ravandi, F.; Keating, M. J.; Gandhi, V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006, 108, 2392-2398. (Pubitemid 44497524)
19. Korycka, A.; Bloński, J. Z.; Robak, T. Forodesine (BCX-1777, Immucillin H)-a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini. Rev. Med. Chem. 2007, 7, 976-983. (Pubitemid 47554785)
20. Robak, T. New nucleoside analogs for patients with hematological malignancies. Expert Opin. Investig. Drugs 2011, 20(3), 343-359.
21. Alonso, R.; López-Guerra, M.; Upshaw, R.; Bantia, S.; Smal, C.; Bontemps, F.; Manz, C.; Mehrling, T.; Villamor, N.; Campo, E.; Montserrat, E.; Colomer, D. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 2009, 114(8), 1563-1575.
22. Cohen, M. H.; Johnson, J. R.; Justice, R.; Pazdur, R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 2008, 13, 709-714. (Pubitemid 351904915)
23. Garcia-Manero, G. Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 2008, 20(6), 705-710.
24. Hollenbach, P. W.; Nguyen, A. N.; Brady, H.; Williams, M.; Ning, Y.; Richard, N.; Krushel, L.; Aukerman, S. L.; Heise, C.; MacBeth, K. J. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5(2), E9001.
25. Garcia-Manero, G.; Fenaux, P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J. Clin. Oncol. 2011, 29(5), 516-523.
26. +-nucleoside cotransporter (hCNT1). Am. J. Physiol. 1997, 272(2 Pt. 1), C707-C714. (Pubitemid 27142601)
27. Ritzel, M. W.; Yao, S. Y.; Ng, A. M.; Mackey, J. R.; Cass, C. E.; Young, J. D. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol. Membr. Biol. 1998, 15(4), 203-211. (Pubitemid 29097592)
28. Wang, J.; Su, S. F.; Dresser, M. J.; Schaner, M. E.; Washington, C. B.; Giacomini, K. M. Na (+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am. J. Physiol. 1997, 273(6 (Pt. 2), F1058-F1065.
29. Smith, K. M.; Ng, A. M.; Yao, S. Y.; Labedz, K. A.; Knaus, E. E.; Wiebe, L. I.; Cass, C. E.; Baldwin, S. A.; Chen, X. Z.; Karpinski, E.; Young, J. D. Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J. Physiol. 2004, 558(Pt. 3), 807-823. (Pubitemid 39199106)
30. Mackey, J. R.; Yao, S. Y.; Smith, K. M.; Karpinski, E.; Baldwin, S. A.; Cass, C. E.; Young, J. D. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl. Cancer Inst. 1999, 91(21), 1876-1881.
31. Lang, T. T.; Young, J. D.; Cass, C. E. Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol. Pharmacol. 2004, 65(4), 925-933. (Pubitemid 38420498)
32. Fotoohi, A. K.; Lindqvist, M.; Peterson, C.; Albertioni, F. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem. Biophys. Res. Commun. 2006, 343(1), 208-215.
33. Fernandez-Veledo, S.; Huber-Ruano, I.; Aymerich, I.; Duflot, S.; Casado, F. J.; Pastor-Anglada, M. Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells. Biochem. J. 2006, 395(2), 337-344.
34. Errasti Murrugarren, E.; Pastor Anglada, M.; Casado, F. J. Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J. Physiol. 2007, 582(Pt. 3), 1249-1260. (Pubitemid 47104352)
35. Ritzel, M. W.; Ng, A. M.; Yao, S. Y.; Graham, K.; Loewen, S. K.; Smith, K. M.; Ritzel, R. G.; Mowles, D. A.; Carpenter, P.; Chen, X. Z.; Karpinski, E.; Hyde, R. J.; Baldwin, S. A.; Cass, C. E.; Young, J. D. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem. 2001, 276(4), 2914-2927.
36. Damaraju, V. L.; Damaraju, S.; Young, J. D.; Baldwin, S. A.; Mackey, J.; Sawyer, M. B.; Cass, C. E. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003, 22(47), 7524-7536. (Pubitemid 37487174)
37. Pastor-Anglada, M.; Molina-Arcas, M.; Casado, F. J.; Bellosillo, B.; Colomer, D.; Gil, J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004, 18(3), 385-393. (Pubitemid 38425849)
38. Osses, N.; Pearson, J. D.; Yudilevich, D. L.; Jarvis, S. M. Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter. Biochem. J. 1996, 317, 843-848. (Pubitemid 26308259)
39. Yao, S. Y.; Ng, A. M.; Vickers, M. F.; Sundaram, M.; Cass, C. E.; Baldwin, S. A.; Young, J. D. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J. Biol. Chem. 2002, 277(28), 24938-24948. (Pubitemid 34951795)
40. King, KM.; Damaraju, V. L.; Vickers, M. F.; Yao, S. Y; Lang, T.; Tackaberry, T. E.; Mowles, D. A.; Ng, A. M.; Young, J. D.; Cass, C. E. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol. 2006, 69(1), 346-353. (Pubitemid 43048921)
41. Weiss, J.; Theile, D.; Ketabi-Kiyanvash, N.; Lindenmaier, H.; Haefeli, W. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 2007, 35(3), 340-344. (Pubitemid 46333919)
42. Servais, A.; Lechat, P.; Zahr, N.; Urien, S.; Aymard, G.; Jaudon, M. C.; Deray, G.; Isnard Bagnis, C. Tubular transporters OAT1 and MRP2 and clearance of adefovir. Nephrol. Ther. 2005, 1(5), 296-300. (Pubitemid 41719288)
43. Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 1999, 36(2), 127-143. (Pubitemid 29121686)
44. de Wolf, C.; Jansen, R.; Yamaguchi, H.; de Haas, M.; van de Wetering, K.; Wijnholds, J.; Beijnen, J.; Borst, P. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol. Cancer Ther. 2008, 7(9), 3092-3102.
45. Hopper-Borge, E.; Xu, X.; Shen, T.; Shi, Z.; Chen, Z. S.; Kruh, G. D. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009, 69(1), 178-184.
46. Guo, Y.; Kotova, E.; Chen, Z. S.; Lee, K.; Hopper-Borge, E.; Belinsky, M. G.; Kruh, G. D. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'8- dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl) adenine. J. Biol. Chem. 2003, 278(32), 29509-29514. (Pubitemid 36962331)
47. Molina-Arcas, M.; Bellosillo, B.; Casado, F. J.; Montserrat, E.; Gil, J.; Colomer, D.; Pastor-Anglada, M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003, 101(6), 2328-2334. (Pubitemid 36304669)
48. Ritzel, M. W.; Ng, A. M.; Yao, S. Y.; Graham, K.; Loewen, S. K.; Smith, K. M.; Hyde, R. J.; Karpinski, E.; Cass, C. E.; Baldwin, S. A.; Young, J. D. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol. 2001, 18(1), 65-72. (Pubitemid 32521598)
49. Robey, R. W.; To, K. K.; Polgar, O.; Dohse, M.; Fetsch, P.; Dean, M.; Bates, S. E. ABCG2: a perspective. Adv. Drug Deliv. Rev. 2009, 61(1), 3-13.
50. Damiani, D.; Tiribelli, M.; Michelutti, A.; Geromin, A.; Cavallin, M.; Fabbro, D.; Pianta, A.; Malagola, M.; Damante, G.; Russo, D.; Fanin, R. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk. Res. 2010, 34(7), 942-945.
51. Dighiero, G.; Hamblin, T. J. Chronic lymphocytic leukaemia. Lancet 2008, 371, 1017-1029. (Pubitemid 351389535)
52. Zenz, T.; Mertens, D.; Kuppers, R.; Dohner, H.; Stilgenbauer, S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 2010, 10(1), 37-50.
53. Chiorazzi, N.; Rai, K. R.; Ferrarini, M. Chronic lymphocytic leukemia. N Engl. J. Med. 2005, 352(8), 804-815.
54. Chiorazzi, N.; Ferrarini, M. Cellular origin (s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011, 117(10), 1781-1791.
55. Caligaris-Cappio, F.; Ghia, P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J. Clin. Oncol. 2008, 26(27), 4497-4503.
56. Munk Pedersen, I.; Reed, J. Microenvironmental interactions and survival of CLL B-cells. Leuk. Lymphoma 2004, 45(1), 2365-2372. (Pubitemid 40081179)
57. Galmarini, CM.; Mackey, J. R.; Dumontet, C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15(6), 875-890. (Pubitemid 32529886)
58. Galmarini, CM.; Mackey, J. R.; Dumontet, C Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002, 3(7), 415-424. (Pubitemid 36958272)
59. Pastor-Anglada, M.; Cano-Soldado, P.; Molina-Arcas, M.; Lostao, M. P.; Larrayoz, I.; Martinez-Picado, J.; Casado, F. J. Cell entry and export of nucleoside analogues. Virus Res. 2005, 107(2), 151-164. (Pubitemid 40093088)
60. O'Brien, S.; Kantarjian, H.; Keating, MJ. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinaemia. Ann. Oncol. 1996, 7(6), S27-S33. (Pubitemid 127552098)
61. Cheson, B. The purine analogs-a therapeutic beauty contest. J. Clin. Oncol. 1998, 10, 352-355.
62. Rai, K. R.; Peterson, B. L.; Appelbaum, F. R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G. A.; Larson, R. A.; Cheson, B. D.; Schiffer, C. A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2000, 343(24), 1750-1757.
63. Rai, K. R.; Peterson, B. L.; Appelbaum, F. R. Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood 2009, abstr 536.
64. Steurer, M.; Pall, G.; Richards, S.; Schwarzer, G.; Bohlius, J.; Greil, R. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst. Rev. 2006, 19(3), CD004270.
65. Johnson, S.; Smith, A. G.; Loffler, H.; Osby, E.; Juliusson, G.; Emmerich, B.; Wyld, P. J.; Hiddemann, W. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996, 347, 1432-1438. (Pubitemid 26161205)
66. Robak, T.; Bloński, J. Z.; Kasznicki, M.; Blasinska-Morawiec, M.; Krykowski, E.; Dmoszynska, A.; Mrugala-Spiewak, H.; Skotnicki, A. B.; Nowak, W.; Konopka, L.; Ceglarek, B.; Maj, S.; Dwilewicz-Trojaczek, J.; Hellmann, A.; Urasiński, I.; Zdziarska, B.; Kotlarek-Haus, S.; Potoczek, S.; Grieb, P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96(8), 2723-2729.
67. Hallek, M. Therapy of chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. 2010, 23(1), 85-96.
68. Brogden, R. N.; Sorkin, E. M. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993, 46(4), 652-677. (Pubitemid 23331064)
69. Johnson, S. A.; Catovsky, D.; Child, J. A.; Newland, A. C.; Milligan, D. W.; Janmohamed, R. Phase I/II evaluation of pentostatin (2-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest. New Drugs 1998, 16(2), 155-160. (Pubitemid 28495217)
70. Ho, A. D.; Thaler, J.; Stryckmans, P.; Coiffier, B.; Luciani, M.; Sonneveld, P.; Lechner, K.; Rodenhuis, S.; Peetermans, M. E.; de Cataldo, F. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J. Natl. Cancer Inst. 1990, 82(17), 1416-1420. (Pubitemid 20261056)
71. Weiss, M. A.; Maslak, P. G.; Jurcic, J. G.; Scheinberg, D. A.; Aliff, T. B.; Lamanna, N.; Frankel, S. R.; Kossman, S. E.; Horgan, D. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2003, 21(7), 1278-1284. (Pubitemid 46606404)
72. Waselenko, J. K.; Grever, M. R.; Beer, M.; Lucas, M. A.; Byrd, J. C. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Semin. Oncol. 2000, 27(2), 44-51. (Pubitemid 30422434)
73. Thursky, K. A.; Worth, L. J.; Seymour, J. F.; Miles Prince, H.; Slavin, M. A. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br. J. Haematol. 2006, 132(1), 3-12. (Pubitemid 43381565)
74. Eichhorst, B. F.; Busch, R.; Hopfinger, G.; Pasold, R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jager, U.; Bergmann, M.; Stilgenbauer, S.; Schweighofer, C.; Wendtner, CM.; Dohner, H.; Brittinger, G.; Emmerich, B.; Hallek, M. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107(3), 885-891. (Pubitemid 43156283)
75. Weiss, M. A.; Glenn, M.; Maslak, P.; Rahman, Z.; Noy, A.; Zelenetz, A.; Scheinberg, D. A.; Golde, D. W. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000, 14(9), 1577-1582.
76. Laurenti, L.; Tarnani, M.; De Padua, L.; Efremov, D. G.; Zini, G.; Garzia, M.; Piccirillo, N.; Chiusolo, P.; Sorà, F.; Innocenti, I.; Sica, S.; Leone, G. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann. Hematol. 2008, 87(11), 891-898.
77. O'Brien, S. M.; Kantarjian, H. M.; Cortes, J.; Beran, M.; Koller, C. A.; Giles, F. J.; Lerner, S.; Keating, M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 2001, 19(5), 1414-1420. (Pubitemid 32202548)
78. Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Grünhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P. L.; Caligaris-Cappio, F.; Seymour, J. F.; Berrebi, A.; Jager, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, CM.; Eichhorst, B. F.; Staib, P.; Buhler, A.; Winkler, D.; Zenz, T.; Bottcher, S.; Ritgen, M.; Mendila, M.; Kneba, M.; Dohner, H.; Stilgenbauer, S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747), 1164-1174.
79. Hillmen, P. Chronic lymphocytic leukaemia-moving towards cure? Lancet 2010, 376(9747), 1122-1124.
80. Molina-Arcas, M.; Marce, S.; Villamor, N.; Huber-Ruano, I.; Casado, F. J.; Bellosillo, B.; Montserrat, E.; Gil, J.; Colomer, D.; Pastor-Anglada, M. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005, 19(1), 64-68. (Pubitemid 40090078)
81. Marce, S.; Molina-Arcas, M.; Villamor, N.; Casado, F. J.; Campo, E.; Pastor-Anglada, M.; Colomer, D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006, 91(7), 895-902. (Pubitemid 44023142)
82. Hubeek, I.; Stam, R. W.; Peters, G. J.; Broekhuizen, R.; Meijerink, J. P.; van Wering, E. R.; Gibson, B. E.; Creutzig, U.; Zwaan, CM.; Cloos, J.; Kuik, D. J.; Pieters, R.; Kaspers, G. J. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 2005, 93(12), 1388-1394. (Pubitemid 41752866)
83. Mackey, J. R.; Galmarini, CM.; Graham, K. A.; Joy, A. A.; Delmer, A.; Dabbagh, L.; Glubrecht, D.; Jewell, L. D.; Lai, R.; Lang, T.; Hanson, J.; Young, J. D.; Merle-Beral, H.; Binet, J. L.; Cass, C. E.; Dumontet, C. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and-insensitive populations. Blood 2005, 105(2), 767-774. (Pubitemid 40070764)
84. Tsang, R.; Santos, C.; Ghosh, S.; Dabbagh, L.; King, K.; Young, J.; Cass, C. E.; Mackey, J. R.; Lai, R. Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Mod. Pathol. 2008, 21, 1387-1393.
85. King, K. M.; Cass, CE. Membrane transport of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabinofluoro-2-deoxyadenosine is required for cytotoxicity. Proc. Am. Assoc. Cancer Res. 1994, 35(A), 3436.
86. Hoellein, A.; Decker, T.; Bogner, C.; Oelsner, M.; Hauswald, S.; Peschel, C.; Keller, U.; Licht, T. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. J. Cancer Res. Clin. Oncol. 2010, 136(3), 403-410.
87. Herweijer, H.; Sonneveld, P.; Baas, F.; Nooter, K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J. Natl. Cancer Inst. 1990, 82(13), 1133-1140. (Pubitemid 20213254)
88. Sonneveld, P.; Nooter, K.; Burghouts, J. T.; Herweijer, H.; Adriaansen, H. J.; van Dongen, J. J. High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992, 79(6), 1496-1500.
89. Svirnovski, A. I.; Shman, T. V.; Serhiyenka, T. F.; Savitski, V. P.; Smolnikova, V. V.; Fedasenka, U. U. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology Am. Soc. Hematol. Educ. Program 2009, 14(4), 204-212.
90. Matthews, C.; Catherwood, M. A.; Larkin, A. M.; Clynes, M.; Morris, T. C.; Alexander, H. D. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk. Lymphoma 2006, 47(11), 2308-2313. (Pubitemid 44768423)
91. Larkin, A.; Moran, E.; Alexander, D.; Clynes, M. Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias. Adv. Exp. Med. Biol. 1999, 457, 65-70. (Pubitemid 129735299)
92. Valdes, R.; Fernandez-Veledo, S.; Aymerich, I.; Casado, F. J.; Pastor-Anglada, M. TGF-beta transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells. Cell Mol. Life Sci. 2006, 63(21), 2527-2537. (Pubitemid 44722382)
93. Klein, K.; Kullak-Ublick, G. A.; Wagner, M.; Trauner, M.; Eloranta, J. J. Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296(4), G936-G947.
94. Leisewitz, A. V.; Zimmerman, E. I.; Huang, M.; Jones, S. Z.; Yang, J.; Graves, L. M. Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun. N-terminal kinase. Biochem. Biophys. Res. Commun. 2011, 404(1), 370-375.
95. Fernandez Calotti, P.; Galmarini, C. M.; Canones, C.; Gamberale, R.; Saenz, D.; Avalos, J. S.; Chianelli, M.; Rosenstein, R.; Giordano, M. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochem. Pharmacol. 2008, 75(4), 857-865.
96. Coe, I.; Zhang, Y.; McKenzie, T.; Naydenova, Z. PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett. 2002, 517(1-3), 201-205. (Pubitemid 34327659)
97. Fernandez Calotti, P.; Pastor Angada, M. All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism. J. Biol. Chem. 2010, 285(18), 13589-13598.